U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb ’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia

PRINCETON, N.J.--(BUSINESS WIRE) May 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486, an investigational oral hypomethylating agent,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news